First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Walgreens Boots Alliance, Inc.

    WBA · 9 developments mapped · last assessed 2026-09-23

    Market Ontology has mapped 9 macro, policy, and market developments to Walgreens Boots Alliance, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for WBA yet, so no modelled value is shown. The WBA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run WBA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for WBA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands

      Increased prescription volume for a high-demand drug, driving pharmacy revenue and foot traffic.

      · Moves pharmacy segment growth rate, prescription volume trends

    • Main threat

      Ulta Beauty, Inc. Announces Second Quarter Fiscal 2026 Results and Acquisition of Space NK

      Increased competition in the beauty retail market, particularly for mass-market and accessible luxury segments.

      · Moves beauty segment market share, competitive pressure

    • Open question

      NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses

      Potential for increased prescription volume for GLP-1 drugs (both branded and compounded) through its retail pharmacy segment, but also pressure on pharmacy margins if compounded options gain significant traction.

      · Moves pharmacy script volume growth, retail pharmacy margins

    What changed, by assumption

    Pharmacy segment growth rate
    • 2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo Expands
    Pharmacy script volume growth
    • 2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Doses
    Increased prescription fulfillment volume
    • 2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli Lilly
    Pharmacy prescription volume growth
    • 2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market Push
    Prescription volume growth
    • 2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMs

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-23Novo Nordisk Rebrands to Novo and Prepares Oral GLP-1 Launch Against Eli LillyBullish1-3m0.40
    2026-09-23Novo Rebrands to 'Novo' and Launches Oral GLP-1 Pill in Obesity Market PushBullish1-3m0.40
    2026-09-18Eli Lilly H1 GLP-1 sales reach $27.7B as oral obesity pill Foundayo secures PBMsmixed3-12m0.40
    2026-09-18Eli Lilly GLP-1 Revenue Hits $27.7B in 1H 2026 as Oral Foundayo ExpandsBullish3-12m0.60
    2026-09-01NexLife Expands Compounded GLP-1 Pricing at $119-$169 Flat Monthly Feemixed3-12m0.30
    2026-09-01NexLife Expands Compounded GLP-1 Plans With Flat $119-$169 Monthly Tiersmixed3-12m0.30
    2026-09-01NexLife Launches Flat-Rate $119-$169 Compounded GLP-1 Programs Across Dosesmixed3-12m0.50
    2026-08-28Ulta Beauty Q2 net sales reach $3.04B with comparable sales up 3.8%mixed1-3m0.30
    2026-08-27Ulta Beauty, Inc. Announces Second Quarter Fiscal 2026 Results and Acquisition of Space NKBearish3-12m0.30